You just read:

Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting

News provided by

Viking Therapeutics, Inc.

Jul 17, 2018, 07:05 ET